Andronis L, Barton P. Adjusting estimates of the expected value of information for implementation: theoretical framework and practical application. Medical Decision Making 2016, 36(3): 296
Andronis L, Barton P. Adjusting the expected value of sample information using realistic expectations around implementation. Medical Decision Making 2016, 36(3): 284
Andronis L, Billingham, L, Bryan S, Barton P. A practical application of value of information and prospective payback of research to prioritise evaluative research. Medical Decision Making 2016, 36(3): 321
Thorn J, Coast J, Andronis L. Interpretation of the expected value of perfect information and research recommendations: a systematic review. Medical Decision Making 2016, 36(3): 285
Duarte R, Andronis L, Lenders M, de Vos C. Quality of life in patients with painful diabetic neuropathy following treatment with spinal cord stimulation. Quality of Life Research 2015 DOI: 10.1007/s11136-015-1211-4. In press.
Popplewell M, Deeks J, Andronis L, Roberts T, Bradbury A. Bypass versus angio plasty in severe ischaemia of the leg - 2 (BASIL-2) trial: study protocol for a randomised controlled trial. Trials 2015 DOI: 10.1186/s13063-015-1114-2. In press
James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I et al. Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel with strontium-89, zoledronic acid, neither, or both. JAMA Oncology 2015. 312-464-JAMA. In press
Mantopoulos T, Mitchell P, Welton N, McManus R, Andronis L. Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results. European Journal of Health Economics 2015. In Press. DOI: 10.1007/s10198-015-0731-8
Andronis L. Analytic approaches for research priority-setting: issues, challenges and the way forward. Expert Review of Pharmacoeconomics and Outcomes Research 2015 Oct;15(5):745-54.
James N, Pirrie S, Pope A, Barton D, Andronis L et al. TRAPEZE: A randomised controlled trial of the clinical and cost effectiveness of chemotherapy with zoledronic acid, strontium-89 or both, in men with bony metastatic castrate refractory prostate cancer. Health Technology Assessment 2015. In press
James N, Andronis L, Goranitis I, Pirrie S, Pope A, Barton D et al. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. J Clin Oncol 33 (suppl; abstr e16108), 2015
Brealey S, Andronis L, Dale V, Gibbon A, Gilbert F and Hendry M. The effect of waiting times from General Practitioner referral to Magnetic Resonance Imaging or orthopaedic consultation for the knee on patient-based outcomes. British Journal of Radiology. 2012 85 (1019): e1134-e1139
Bryan S, Dormandy E, Roberts T, Ades A, Barton P, Juarez-Garcia A, Andronis L, Karnon J and Marteau T. Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study. British Journal of General Practice 2011; 61(591):620-627
Barton P, Andronis L, Briggs A, McPherson K and Capewell S. Effectiveness and cost-effectiveness of cardiovascular disease prevention in whole populations: modelling study. British Medical Journal 2011 28: 343
Ashfaq K, Yahaya I , Hyde C, Andronis L, Barton P, Bayliss S et al. Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technology Assessment 2010 Dec;14(54):iii-xi, 1.
Brealey S, Andronis L, Dennis L, Atwell C, Bryan S, Coulton S et al. Participants' preference for type of leaflet used to feed back the results of a randomised trial: a survey. Trials 2010;11:16.
Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, Andronis L et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technology Assessment 2010 Oct;14(50):1-103.
Bryan S, Andronis L, Hyde C, Connock M, Fry-Smith A and Wang D. Infliximab for the treatment of acute exacerbations of ulcerative colitis. Health Technology Assessment 2010 May;14 Suppl 1:9-15.
Hyde C, Bryan S, Juarez-Garcia A, Andronis L and Fry-Smith A. Infliximab for the treatment of ulcerative colitis. Health Technology Assessment 2009 Oct;13 Suppl 3:7-11.
Andronis L, Barton P and Bryan S. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technology Assessment 2009 Jun;13(29):iii, ix-61.
DAMASK Trial Team (Brealey S, Andronis L, Atwell C, Bryan S, Collins S, Coulton S et al.) Effectiveness of GP access to MRI of the knee: a randomised trial. British Journal of General Practice 2008; 58(556): e1-8
DAMASK Trial Team (Brealey S, Andronis L, Atwell C, Bryan S, Collins S, Coulton S et al.) Cost effectiveness of magnetic resonance imaging of the knee for patients presenting in primary care. British Journal of General Practice 2008; 58(556): e10-16